Skip to main content
Full access
Letters to the Editor
Published Online: 1 September 2022

Treatments for Depression in Bipolar II Disorder

Publication: American Journal of Psychiatry
To the Editor: We read with interest Dr. Ostacher’s December 2021 editorial (1) regarding the article “Efficacy and Safety of Lumateperone for Major Depressive Episodes Associated with Bipolar I or Bipolar II Disorder: A Phase 3 Randomized Placebo-Controlled Trial,” by Calabrese et al. (2). We are pleased to offer context and several points of clarification regarding Dr. Ostacher’s comments concerning both general challenges of bipolar clinical trials and specific points raised in reference to our study.
Diagnosis of bipolar disorder remains a challenge for research as well as in clinical practice. We agree with Dr. Ostacher that diagnosis can be problematic in studies of acute bipolar depression, particularly for subjects with bipolar II disorder. While all psychiatric diagnoses are established on clinical grounds, the sample enrolled in research studies, such as ours, use rigorous methods to enhance diagnostic confidence. In addition to a thorough patient history, determination of eligibility for our study included multiple validated structured assessments including screening using the Mini-International Neuropsychiatric Interview (M.I.N.I.) (3) and the Montgomery-Åsberg Depression Rating Scale (MADRS) (4), administered by trained raters. Such methodology offers important, though still imperfect, protection against the modest inter-rater reliability for common psychiatric conditions observed in DSM-5 Field Trials (5). Additionally, random assignment to parallel treatment groups balances the impact of potential diagnostic errors on clinical trial results. Such errors would be associated with higher placebo response and hence would militate against the detection of drug-placebo effects (6).
Dr. Ostacher raised concern about the potential influence of functional unblinding. He suggests the imbalance in somnolence (8.5% with lumateperone vs. 1.1% with placebo) and nausea (6.4% vs. 2.1%) could bias raters and possibly exaggerate the true drug-placebo difference. While this is a potential concern, the lumateperone-placebo differences in somnolence (7.4%) and nausea (4.3%) are quite modest, and considerably smaller than some agents used in bipolar disorder, including quetiapine (7, 8). Nevertheless, to examine this question, we conducted analyses (shown in Table 1) of the change from baseline in MADRS total score at day 43, excluding patients reporting one or either of these adverse events. As seen in Table 1, reporting of these adverse events did not influence results in this study, as lumateperone efficacy was nearly the same in the analysis based on all patients (−4.6 points) versus the three other analyses (−4.5 to −4.6 points) which excluded those patients reporting somnolence and/or nausea.
TABLE 1. Comparison of change from baseline in MADRS total score at day 43 between lumateperone 42 mg and placebo treatment groupsa
 Change from Baseline at Day 43 in MADRS Total Score
Analysis (MMRM)LS Mean Difference95% CIp
All patients included (intent-to-treat)−4.6(−6.34, −2.83)<0.0001
Excluded patients with adverse event of somnolence−4.5(−6.31, −2.68)<0.0001
Excluded patients with adverse event of nausea−4.6(−6.4, −2.86)<0.0001
Excluded patients with adverse events of somnolence and/or nausea−4.5(−6.35, −2.74)<0.0001
a
CI, confidence interval; LS, least squares; MADRS, Montgomery-Åsberg Depression Rating Scale; MMRM, mixed-effects model for repeated measures.
As mentioned above, the potential for functional unblinding was low in our study because the adverse event rate, both relative to placebo as well as in absolute terms, was low in comparison to the adverse event profile reported in studies of other FDA-approved drugs for treatment of bipolar depression (e.g., quetiapine, quetiapine XR, lurasidone, cariprazine), which reported double digit rates of extrapyramidal symptom-related events or somnolence in their Prescribing Information (710).
Additionally, issues were raised regarding the sample size, effect size, least square mean difference, and confidence interval (CI) of patients with bipolar II disorder. The patient randomization of the study was stratified by bipolar type, which produced two treatment groups of bipolar II patients balanced at baseline. This procedure meets the assumption of ceteris paribus required for fair comparability and assessment of the treatment effect within each bipolar type. Even though the sample size of bipolar II patients was relatively low, the p value for the comparison between lumateperone and placebo was <0.001 for the primary endpoint and <0.01 for the key secondary endpoint, supporting the efficacy of lumateperone in patients with bipolar II disorder. The critique of a wide CI on the treatment effect of lumateperone versus placebo in bipolar II disorder also has little merit. While there was a wide CI for the change from baseline at day 43 in MADRS total score least squares (LS) mean difference in those with bipolar II disorder (LS mean difference, −7.0, 95% CI=−10.92, −3.16; effect size −0.81), the upper bound of −3.16 indicates there is 97.5% confidence that the lumateperone placebo-adjusted effect in bipolar II is at least 3.16 points of change from baseline in MADRS total score.
Maintaining skepticism is appropriate but lingering questions should not obscure the preponderance of evidence provided by rigorous clinical trials. Based on the totality of evidence, the FDA approved lumateperone for the treatment of depressive episodes associated with bipolar I or II disorder as monotherapy and as adjunctive therapy with lithium or valproate in adults in December 2021.
We appreciate the opportunity to respond to the issues raised in the editorial.

References

1.
Ostacher MJ: Slowly working toward more treatments for depression in bipolar II disorder. Am J Psychiatry 2021; 178:1075–1076
2.
Calabrese JR, Durgam S, Satlin A, et al: Efficacy and safety of lumateperone for major depressive episodes associated with bipolar I or bipolar II disorder: a phase 3 randomized placebo-controlled trial. Am J Psychiatry 2021; 178:1098–1106
3.
Sheehan DV, Lecrubier Y, Sheehan KH, et al: The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998; 59:22–33; quiz 34–57
4.
Montgomery SA, Åsberg M: A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134:382–389
5.
Regier DA, Narrow WE, Clarke DE, et al: DSM-5 field trials in the United States and Canada, Part II: test-retest reliability of selected categorical diagnoses. Am J Psychiatry 2013; 170:59–70
6.
Sachs GS, Vanderburg DG, Edman S, et al: Adjunctive oral ziprasidone in patients with acute mania treated with lithium or divalproex, part 2: influence of protocol-specific eligibility criteria on signal detection. J Clin Psychiatry 2012; 73:1420–1425
7.
Seroquel. Prescribing information. AstraZeneca Pharmaceuticals, 2020
8.
Seroquel XR. Prescribing information. AstraZeneca Pharmaceuticals, 2020
9.
Vraylar. Prescribing information. Allergan, 2019
10.
Latuda. Prescribing information. Sunovion, 2018

Information & Authors

Information

Published In

Go to American Journal of Psychiatry
Go to American Journal of Psychiatry
American Journal of Psychiatry
Pages: 688 - 690

History

Received: 27 January 2022
Accepted: 21 March 2022
Published online: 1 September 2022
Published in print: September 2022

Keywords

  1. Bipolar and Related Disorders
  2. Bipolar II Disorder
  3. Clinical Drug Studies
  4. Pharmacotherapy
  5. Antipsychotics
  6. Second Generation

Authors

Details

Suresh Durgam, M.D. [email protected]
Intra-Cellular Therapies, Inc., New York (Durgam, Chen); Department of Psychiatry, Case Western Reserve School of Medicine, Cleveland, and University Hospitals Cleveland Medical Center, Cleveland (Calabrese); Massachusetts General Hospital, Boston, and Signant Health, Plymouth Meeting, Pa. (Sachs).
Richard Chen, Ph.D.
Intra-Cellular Therapies, Inc., New York (Durgam, Chen); Department of Psychiatry, Case Western Reserve School of Medicine, Cleveland, and University Hospitals Cleveland Medical Center, Cleveland (Calabrese); Massachusetts General Hospital, Boston, and Signant Health, Plymouth Meeting, Pa. (Sachs).
Joseph R. Calabrese, M.D.
Intra-Cellular Therapies, Inc., New York (Durgam, Chen); Department of Psychiatry, Case Western Reserve School of Medicine, Cleveland, and University Hospitals Cleveland Medical Center, Cleveland (Calabrese); Massachusetts General Hospital, Boston, and Signant Health, Plymouth Meeting, Pa. (Sachs).
Gary S. Sachs, M.D.
Intra-Cellular Therapies, Inc., New York (Durgam, Chen); Department of Psychiatry, Case Western Reserve School of Medicine, Cleveland, and University Hospitals Cleveland Medical Center, Cleveland (Calabrese); Massachusetts General Hospital, Boston, and Signant Health, Plymouth Meeting, Pa. (Sachs).

Notes

Send correspondence to Dr.Durgam ([email protected]).

Competing Interests

Dr. Calabrese has served as an advisory board member and/or consultant for Alkermes, Janssen Research and Development, Otsuka Pharmaceutical Development and Commercialization, and Sunovion Pharmaceuticals; he has served as a consultant and received travel funds from Intra-Cellular Therapies, Inc.; and he has served on the speakers bureau for Sumitomo Dainippon Pharma. Drs. Durgam and Chen are employees of Intra-Cellular Therapies, Inc., and hold company stock and/or stock options. Dr. Sachs is an employee of Signant Health.

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

View Options

View options

PDF/EPUB

View PDF/EPUB

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - American Journal of Psychiatry

PPV Articles - American Journal of Psychiatry

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share